Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (2)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2019 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue is to raise capital for the continued development of projects and to strengthen the company’s shareholder base.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Joel Magnusson.

Related

Vinge advises Impilo on the establishment of a continuation fund

 Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.
November 15, 2024

Vinge advises Österlens Kraft economic association in connection with the sale of all shares in Österlens Kraft Fjärrvärme AB to Adven Sverige AB

 Österlens Kraft Fjärrvärme AB produces, distributes and sells district heating to the company's customers in Simrishamn.
November 14, 2024

Vinge advises Abacus Bidco Oy (which is the parent company of Accountor Software recently acquired by KKR) in the acquisition of certain subsidiaries and assets of 24SevenOffice Group AB (“24SevenOffice”)  

 24SevenOffice is a listed company (First North Stockholm) that provides modular software for accounting, ERP and business services that automate processes using AI.
November 13, 2024